Incyte Corporation (INCY)

Incyte's stock price has experienced several notable events in the past six months. The stock was up 11.3% over this period and 68.60% over the past year. Health Canada approved Opzelura cream for treating atopic dermatitis in children, leading to a 1.5% jump in the stock price and a raised price target from Stifel. The stock saw a positive drift with a 1.7% gain on December 4, 2024, after gapping up 1.9% at the open, but lost 2.3% on December 19, 2024, after gapping up 1.6%. Incyte reported its Fourth Quarter and Full Year 2025 financial results on February 10, 2026, which led to an 8% drop in the stock price due to adjusted EPS missing expectations and the 2026 guidance for Opzelura sales falling short of consensus. On March 6, 2026, Incyte announced the European Commission's approval of Zynyz for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). On March 9, 2026, the U.S. FDA issued a Complete Response Letter (CRL) for Incyte's supplemental biologics license application for Zynyz in first-line non-small cell lung cancer, citing unresolved inspection findings at a third-party manufacturing facility. On March 28, 2026, Incyte announced new positive 54-week late-breaking data for Povorcitinib in Hidradenitis Suppurativa, leading Citizens to reiterate a "Market Perform" rating. Jefferies downgraded Incyte to 'Hold' due to concerns over the Jakafi patent expiration in 2028.

UBS has cited revenue concerns related to seasonality in Incyte's Opzelura and Jakafi products, which may lead to a topline revenue miss, indicating that demand for at least some of Incyte's key products experiences seasonal fluctuations.

Incyte Corp. is a global biopharmaceutical company focused on discovering, developing, and commercializing proprietary therapeutics, operating primarily in the Healthcare sector within the Pharmaceuticals: Major and Biotechnology industries. Incyte's business is centered on addressing unmet medical needs through a portfolio of medicines and a pipeline concentrated in Oncology and Inflammation & Autoimmunity. The company's marketed products include Jakafi for rare blood cancers and graft-versus-host disease, Opzelura cream for atopic dermatitis and nonsegmental vitiligo, Pemazyre for cholangiocarcinoma, Monjuvi/Minjuvi for diffuse large B-cell lymphoma and follicular lymphoma, Iclusig for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia, Tabrecta for lung cancer, Niktimvo for chronic graft-versus-host disease, and Zynyz for Merkel cell carcinoma and advanced squamous cell carcinoma of the anal canal.

Incyte has a global presence with operations in North America, Europe, and Asia. In addition to its Delaware headquarters, the company has a European headquarters in Morges, Switzerland, and offices in Japan, Germany, Italy, Spain, the United Kingdom, Denmark, Finland, Sweden, Austria, France, the Netherlands, and Canada. In May 2024, Incyte expanded its U.S. footprint by acquiring two new buildings in downtown Wilmington, Delaware, to consolidate its U.S. commercial and medical affairs teams.

Incyte maintains a reputation as a global biopharmaceutical company committed to scientific investment and R&D excellence to develop solutions for patients with unmet medical needs. The company actively promotes patient and community engagement through initiatives like the "MPN Heroes®" program and the "Incyte Ingenuity Awards." Regulatory approvals and positive clinical trial data contribute to a strong scientific reputation. However, the FDA's Complete Response Letter for Zynyz in lung cancer could be perceived as a setback.

Incyte's ownership is predominantly institutional, with 833 institutional owners holding a total of 199,636,671 shares as of April 9, 2026. Major institutional owners include Baker Bros. Advisors LP, The Vanguard Group, Inc., BlackRock Institutional Trust Company, N.A., Dodge & Cox, State Street Investment Management (US), AQR Capital Management, LLC, Geode Capital Management, LLC, Renaissance Technologies LLC, LSV Asset Management, Invesco Ltd., BNP PARIBAS ASSET MANAGEMENT Holding S.A., Jane Street Group, and Gotham Asset Management. Insider trading activity in early 2026 included sales by officers Sheila A. Denton, Lee Heeson, and Patrick A. Mayes, and director Edmund P. Harrigan, M.D.